期刊文献+

自体造血干细胞动员的研究进展 被引量:2

Advances in mobilization of autologous hematopoietic stem cells
原文传递
导出
摘要 自体造血干细胞移植(auto-HSCT)具有造血功能重建和免疫功能恢复迅速、并发症和相关死亡率低等显著临床优势,已成为高度侵袭性、复发/难治性非霍奇金淋巴瘤(NHL)和多发性骨髓瘤(MM)患者的常规治疗选择[1-2].外周血干细胞(PBSC)获取便利,免于骨髓穿刺和麻醉,且有造血功能重建快、患者生活质量较好和降低成本等优势,已成为auto-HSCT的主要干细胞来源[3].2012年全球移植数据显示,在36220例auto-HSCT中,99%为PBSC移植[4].auto-HSCT成功的关键是PBSC的数量和质量,但是正常人PBSC含量很低[5],动员骨髓中的干细胞迁移至外周血,提高PBSC浓度是进行auto-HSCT的关键.目前我国临床常用的动员方案包括大剂量化疗、单用粒细胞集落刺激因子(G-CSF)、G-CSF联合化疗,此外尚有许多临床研究仍在进行中.
作者 陈欢 刘开彦 Chen Huan;Liu Kaiyan(Peking University People’s Hospital,Peking University Institution of Hematology,National Clinical Reserarch Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,China)
出处 《中华血液学杂志》 CAS CSCD 北大核心 2019年第10期884-888,共5页 Chinese Journal of Hematology
  • 相关文献

参考文献1

二级参考文献13

  • 1Rajkumar SV. Treatment of multiple myeloma [J]. Nat Rev Clin Oncol, 2011, 8(8):479-491.
  • 2Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma [J]. Leukemia, 2009, 23 ( 1 ):3-9.
  • 3Greipp PR, San Mignel J, Durie BG, et al. International staging system for multiple myeloma [J]. J Clin Oncol, 2005, 23 (15): 3412-3420.
  • 4Wuchter P, Ran D, Bruckner T, et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of antologous transplantation[J]. Biol Blood Marrow Transplant, 2010, 16(4):490-499.
  • 5Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral- blood stem cells[J]. J Clin Oncol, 1995, 13( 10):2547-2555.
  • 6Stiff P J, Micallef I, Nademanee AP, et al. Transplanted CD34 (+) cell dose is associated with long-term platelet count recov- ery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma [J]. Biol Blood Marrow Transplant, 2011, 17 ( 8 ): 1146-1153.
  • 7Duong HK, Savani BN, Copelan E, et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation [J]. Biol Blood Marrow Transplant, 2014, 20(9): 1262-1273.
  • 8Cavo M, Rajkumar SV, Palumbo A, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation[J]. Blood, 2011, 117(23):6063-6073.
  • 9Olivieri A, Marchetti M, Lemoli R, et al. Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo [J]. Bone Marrow Transplant, 2012, 47(3):342-351.
  • 10Gertz MA, Wolf RC, Micallef IN, et al. Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma [J]. Bone Marrow Transplant, 2010, 45(9): 1396-1403.

共引文献16

同被引文献13

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部